<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581447</url>
  </required_header>
  <id_info>
    <org_study_id>P170901J</org_study_id>
    <secondary_id>2019-000312-28</secondary_id>
    <secondary_id>PHRCN-17-0337</secondary_id>
    <nct_id>NCT04581447</nct_id>
  </id_info>
  <brief_title>Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care</brief_title>
  <acronym>DiabOUT</acronym>
  <official_title>Extending Time Without Diabetes After Bariatric Surgery: a Randomized Controlled Trial Comparing the Metformin Addition or Not to Standard Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized trial that evaluates the effect of metformin addition or not to&#xD;
      standard care on the duration of diabetes remission after bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to significant weight loss, several randomized control trials (RCTs) have&#xD;
      demonstrated that bariatric surgery can reverse or at least improve type 2 diabetes (T2D).&#xD;
      Despite the variability in study design and patient characteristics of these RCTs, there is a&#xD;
      consistent favorable effect of surgery compared to medical treatment for weight loss, change&#xD;
      in HbA1c, reduction in diabetes medications, remission of metabolic syndrome and improvement&#xD;
      in quality of life. Diabetes remission rate is estimated from 15 to 45 % according to the 4&#xD;
      available RCT including the most used surgery (Roux-en-Y gastric bypass (RYGB) and sleeve&#xD;
      gastrectomy (SG)) with at least three to five years of follow-up. These results mean that&#xD;
      more than half of patients with type 2 diabetes are still or newly diagnosed with diabetic&#xD;
      after surgery and that extending time of diabetes remission after bariatric surgery is of&#xD;
      major concern.&#xD;
&#xD;
      No RCT has explored yet an intervention to extend diabetes remission. Apart from bariatric&#xD;
      surgery, metformin is unequivocally recommended to treat both diabetes and pre-diabetes along&#xD;
      with lifestyle interventions. Results of the Diabetes Prevention Program trial showed that&#xD;
      metformin reduces diabetes incidence by 31% in obese patients with pre-diabetes. We&#xD;
      hypothesized that metformin might extend the duration of diabetes remission after bariatric&#xD;
      surgery.&#xD;
&#xD;
      The study is a randomized, controlled, open-labeled, multicenter trial.&#xD;
&#xD;
      Patients fulfilling the inclusion criteria and without any of the exclusion criteria will be&#xD;
      randomized.&#xD;
&#xD;
      Patients will receive:&#xD;
&#xD;
        -  Standardized care plus metformin treatment if randomized in the experimental group given&#xD;
           for 3 years&#xD;
&#xD;
        -  Standardized care alone if randomized in the reference group&#xD;
&#xD;
      Primary objective is to demonstrate that metformin increases the proportion of patients with&#xD;
      T2D remission compared to standard care among ex-T2D patients operated of BS, after a 3-year&#xD;
      period of treatment.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To assess the proportion of patients with T2D partial or complete remission with&#xD;
           metformin compared to standard care in ex-T2D patients operated of BS, after 1 and 2&#xD;
           years of treatment.&#xD;
&#xD;
        -  To assess body weight and metabolic parameters in metformin group versus standard care.&#xD;
&#xD;
        -  To assess tolerance, nutritional status and adherence to metformin in intervention group&#xD;
           versus standard care.&#xD;
&#xD;
        -  To assess micro and macroangiopathy at 3 years.&#xD;
&#xD;
        -  To assess quality of life changes from baseline at 1, 2 and 3 years.&#xD;
&#xD;
        -  To assess the accuracy of long term prediction score (i.e. prolonged remission assessed&#xD;
           at the end of the study with the Ad-DiaRem score)&#xD;
&#xD;
        -  To explore gut microbiota differences (diversity, composition and function) between&#xD;
           metformin treated and non-treated individuals&#xD;
&#xD;
      Patients are followed up every 4 months during 3 years in both arms. If diabetes is diagnosed&#xD;
      during the follow-up (HbA1c &gt; 6.5 %), the primary endpoint of the study is obtained meaning&#xD;
      end of diabetes remission but patients will be still followed up to the end of protocol to&#xD;
      monitor the secondary endpoints. When remission is over, the care defined by the protocol (ie&#xD;
      metformin + standardized care or standardized care alone) should be stopped. In both groups,&#xD;
      when remission is over, management of the disease has to be adapted according to physician's&#xD;
      and patient's preference whatever the arm of randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with partial or complete T2D remission criteria</measure>
    <time_frame>3 years</time_frame>
    <description>Complete remission: HbA1c&lt;5.7% and no anti-diabetic medications (except metformin in the experimental group).&#xD;
Partial remission: defined as prediabetes level of glycaemia i.e. HbA1c&lt;6.5% and no anti-diabetic medications (except metformin in the experimental group).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with partial or complete T2D remission criteria</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Complete remission: HbA1c&lt;5.7% and no anti-diabetic medications (except metformin in the experimental group).&#xD;
Partial remission: defined as prediabetes level of glycaemia i.e. HbA1c&lt;6.5% and no anti-diabetic medications (except metformin in the experimental group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with strict complete T2D remission criteria</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of weight and BMI change</measure>
    <time_frame>1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glycemia</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Assessment of the level of cardio-metabolic parameters associated to T2D. Fasting glycemia and insulinemia will be combined to report HOMA-IR (homeostatic model assessment - insulin resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulinemia</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Assessment of the level of cardio-metabolic parameters associated to T2D. Fasting glycemia and insulinemia will be combined to report HOMA-IR (homeostatic model assessment - insulin resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood triglycerides</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Assessment of the level of cardio-metabolic parameters associated to T2D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood HDL cholesterol</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Assessment of the level of cardio-metabolic parameters associated to T2D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Systolic and diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood albumin</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood hemoglobin</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood iron</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of serum ferritin</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation percentage</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood calcium</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood vitamin D</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood vitamin B1</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood vitamin B9</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of blood vitamin B12</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Level of nutritional parameters associated with BS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse effects in the intervention group compared to standard care</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pills taken per patient</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Adherence level assessment in the intervention group. Compliant patients are defined as taking at least 80% of assigned study pills in the intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of plasmatic metformin</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Adherence level assessment in the intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of retinopathy events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of nephropathy events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of macroangiopathy events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and proportions of patients with quality of life changes</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>assessed by EuroQol 5 Dimensions (EQ5D) auto-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at the end of the study</measure>
    <time_frame>3 years</time_frame>
    <description>assessed by 5-year-Advanced-Diabetes Remission (5y-Ad-DiaRem) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbiota</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Diabetes</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Metformin</condition>
  <arm_group>
    <arm_group_label>Metformin + Standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).&#xD;
All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily</description>
    <arm_group_label>Metformin + Standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Standard Care</description>
    <arm_group_label>Metformin + Standard care</arm_group_label>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18-70 years old&#xD;
&#xD;
          -  Having undergone gastric bypass or sleeve gastrectomy 12 to 24 +/-3 months before&#xD;
             inclusion&#xD;
&#xD;
          -  &quot;ex-T2D&quot; treated with at least one anti-diabetic drug before bariatric surgery&#xD;
&#xD;
          -  HbA1C &lt; 6.5 % at inclusion with no anti-hyperglycemic medications for the last three&#xD;
             months&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known type 1 diabetes&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Estimated glomerular filtration rate&lt;44 ml/min (MDRD)&#xD;
&#xD;
          -  Known intolerance to metformin&#xD;
&#xD;
          -  Known contraindication to metformin:&#xD;
&#xD;
               -  Acute metabolic acidosis&#xD;
&#xD;
               -  Acute affection which could lead to renal deterioration (ex: dehydration, serious&#xD;
                  infection, shock, intravascular administration of iodinated contrast agent within&#xD;
                  the last 48 hours)&#xD;
&#xD;
               -  Acute or chronic disease which could lead to a tissue hypoxia (ex : severe&#xD;
                  cardiac insufficiency, severe respiratory insufficiency, myocardial infarction&#xD;
                  within the last 3 months, shock)&#xD;
&#xD;
               -  Hepatocellular insufficiency&#xD;
&#xD;
               -  Prothrombin ratio ≤ 50%&#xD;
&#xD;
               -  SGOT or SGPT levels ≥ 10 times the upper limits of the normal range&#xD;
&#xD;
               -  Alcohol use disorder&#xD;
&#xD;
          -  Medications and medical conditions likely to confound the assessment of diabetes:&#xD;
&#xD;
               -  glucocorticoids treatment&#xD;
&#xD;
               -  renal graft&#xD;
&#xD;
               -  Cushing's syndrome&#xD;
&#xD;
               -  acromegaly&#xD;
&#xD;
               -  fasting plasma triglyceride &gt; 600 mg/dl despite treatment&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire CARETTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>claire.carette@aphp.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie GUIMFACK</last_name>
    <email>aurelie.guimfack@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvann FRIGOUT</last_name>
    <email>yvann.frigout@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens-Picardie - hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Daniel Lalau, MD</last_name>
      <email>lalau.jean-daniel@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Bihan, MD</last_name>
      <email>helene.bihan@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud Monsaingeon-Henry, MD</last_name>
      <email>maud.monsaingeon-henry@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital Ambroise-Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Bretault, MD</last_name>
      <email>marion.bretault@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital Louis-Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine Ledoux, MD</last_name>
      <email>severine.ledoux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Perle Sayedoff, MD</last_name>
      <email>perle.sayedoff@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lille - hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène Verkindt, MD</last_name>
      <email>helene.verkindt@chu-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte Gaborit, MD</last_name>
      <email>benedicte.gaborit@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte Gaborit, MD</last_name>
      <email>benedicte.gaborit@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Carette, MD</last_name>
      <email>claire.carette@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Hansel, MD</last_name>
      <email>boris.hansel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Ciangura, MD</last_name>
      <email>cecile.ciangura@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Pourcher, MD</last_name>
      <email>guillaume.pourcher@imm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCL - centre hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Disse, MD</last_name>
      <email>emmanuel.disse@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Saint-Denis - hôpital Delafontaire</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc Catheline, MD</last_name>
      <email>jeanmarc.catheline@ch-stdenis.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ritz, MD</last_name>
      <email>ritz.p@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <keyword>Gastric bypass</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Two years after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered.&#xD;
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization. Processing of shared data must comply with European General Data Protection Regulation (GDPR).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

